Potential Clues to the Pathogenesis of Acquired Hemophilia

Jecko Thachil

doi:10.1055/s-0040-1722294

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2021; 47(07): 890-891
DOI: 10.1055/s-0040-1722294

Letter to the Editor

Potential Clues to the Pathogenesis of Acquired Hemophilia

Jecko Thachil

¹Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom

References
1 van der Zwan M, Leebeek FWG, Sandberg Y, Kruip MJHA, Hesselink DA. Acquired haemophilia A after alemtuzumab therapy. Haemophilia 2020; 26 (06) e337-e339
2 Comini-Frota ER, Campos APF, Neto APG, Christo PP. Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: a report of two cases. Mult Scler Relat Disord 2020; 44: 102181
3 Brink HS, Moll W, Sandberg Y. Acquired haemophilia A after alemtuzumab treatment of multiple sclerosis. Br J Haematol 2020; 190 (01) 13
4 Massey J, Barnett Y, Curnow J, Sutton I. B cell depletion therapy resulting in sustained remission of severe autoimmune complications following alemtuzumab treatment of multiple sclerosis. Mult Scler Relat Disord 2019; 35: 100-103
5 Pisa M, Della Valle P, Coluccia A. et al. Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report. Mult Scler Relat Disord 2019; 27: 403-405
6 Madeley J, Hodges G, Birchley A. Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis. BMJ Case Rep 2018; 2018: bcr2018226588
7 McCaughan G, Massey J, Sutton I, Curnow J. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis. BMJ Case Rep 2017; 2017: bcr2017223016
8 Devonshire V, Phillips R, Wass H, Da Roza G, Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations. J Neurol 2018; 265 (11) 2494-2505
9 Hu GL, Okita DK, Diethelm-Okita BM, Conti-Fine BM. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003; 1 (10) 2159-2166
10 Reding MT, Wu H, Krampf M. et al. Sensitization of CD4+ T cells to coagulation factor VIII: response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84 (04) 643-652
11 Varthaman A, Lacroix-Desmazes S. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?. Haematologica 2019; 104 (02) 236-244
12 Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017; 74 (08) 961-969
13 Nishimoto T, Kuwana M. CD4+CD25+Foxp3+ regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 2013; 50 (Suppl. 01) S43-S49
14 Aggarwal A, Grewal R, Green RJ. et al. Rituximab for autoimmune haemophilia: a proposed treatment algorithm. Haemophilia 2005; 11 (01) 13-19
15 Zaja F, Vianelli N, Battista M. et al. Earlier administration of rituximab allows higher rate of long-lasting response in adult patients with autoimmune thrombocytopenia. Exp Hematol 2006; 34 (05) 571-572